GlaxoSmithKline Pharmaceuticals (500660) investor relations material

Executive summary

• Achieved strong, profitable growth in Q1 FY27, driven by portfolio transformation, innovation, and execution excellence.

• Innovation portfolio contributed significantly to growth, with new launches in oncology and respiratory segments and now accounting for 7% of revenues, nearly doubling from last year.

• Maintained leadership in key therapy areas and vaccines, with competitive performance from promoted brands and balanced growth across geographies and customer segments.

• Unaudited standalone and consolidated financial results for the quarter ended 30th June 2026 were approved by the Board on 3rd August 2026.

• Board changes include the resignation of a Non-Executive Director, appointment of a new Non-Executive Director, and re-appointment of the Managing Director for two years from December 2026.

Financial highlights

• Revenue reached ₹924 crore, up 15% year-over-year; standalone and consolidated net profit for Q1 FY27 was ₹25,333 lakhs and ₹23,718 lakhs, respectively.

• EBITDA was ₹293 crore, up 17% year-over-year, with margin at 31.7% (+50 bps YoY); PAT margin at 27.6%, up 200 bps YoY.

• EPS for Q1 was ₹14.95, up 24% year-over-year.

• Gross margin improved by 150 bps due to pricing and favorable mix.

• Final dividend of ₹57 per equity share for FY26 was approved at the AGM held on 30th June 2026.

Outlook and guidance

• Expect continued double-digit growth, driven by established and innovative products, with a focus on accelerating R&D and simplifying operations.

• Upcoming launches include Blenrep, Ojjaara, Arexvy, and other oncology, respiratory, and vaccine products within the next 18-24 months.

• SG&A ratios and OpEx expected to normalize in coming quarters after a deliberate Q1 investment spike.

• The company aims to double sales of its General Medicines growth engines by 2030 and reach over 1 billion patients this decade.